CWBHF earnings analysis
What we found in CWBHF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Charlotte’s Web delivered a mixed Q2: revenue fell 15.2% year over year to $10.855 million and the operating loss widened to $4.358 million, but gross margin improved to 47.5%, SG&A declined 5.4%, and operating cash use improved materially. The BAT transaction strengthened the balance sheet, increasing cash to $13.988 million and reducing liabilities to $20.325 million, although it resulted in BAT owning approximately 40.6% of the company. Management provided no numeric guidance, but expects continued cost containment and believes liquidity is sufficient for the next 12 months.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Gross Margin Expanded
- Q2 revenue was $10.855 million, while gross margin improved to 47.5% from 46.8% in Q2 2025, an increase of approximately 70 basis points despite lower sales.
- SG&A Cost Reduction
- Selling, general and administrative expense declined 5.4% year over year to $9.515 million from $10.062 million, reflecting cost-cutting measures.
- Operating Cash Burn Improved
- Net cash used in operating activities improved to $3.705 million for the six months ended June 30, 2026, from $6.786 million in the prior-year period.
- Capital Spending Remained Low
- Investing cash use was only $45 thousand for the first six months of 2026 versus $539 thousand in the prior-year period, reflecting minimal capital expenditures.
- Liquidity Position Improved
- Cash and cash equivalents increased to $13.988 million at June 30, 2026 from $8.035 million at December 31, 2025, while current liabilities declined to $8.256 million from $8.659 million.
- BAT Transaction Reduced Leverage
- BAT converted the C$75.3 million convertible debenture and $10.3 million of accrued interest, totaling approximately $65 million, into equity and made a further $10 million investment; total liabilities fell to $20.325 million from $73.047 million year over year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Decline From Channel Shift
- Q2 total revenue declined 15.2% to $10.855 million from $12.806 million, and six-month revenue declined 12.2% to $22.014 million from $25.068 million. Management attributed the decline to shifting the majority of retail business to a distributor model during the third quarter of 2025.
- Operating Loss Remains Significant
- The company reported a Q2 operating loss of $4.358 million on $10.855 million of revenue, equivalent to an operating margin of approximately negative 40.1%, compared with a $4.072 million operating loss and approximately negative 31.8% margin in Q2 2025.
- Year-to-Date Margin Pressure
- Six-month gross margin fell to 47.1% from 48.7%, a decline of approximately 160 basis points, as other production costs increased 9.8% to $3.663 million and depreciation and amortization in cost of goods sold increased 19.3% to $1.921 million.
- Dependence on Future Financing
- The company used $3.705 million in operating cash during the first six months of 2026 and states that longer-term liquidity depends on revenue growth and expense management; it may need additional borrowings or equity issuances.
- Ownership Concentration and Dilution
- The BAT transaction issued 109,944,042 common shares, leaving BAT with approximately 40.6% of outstanding shares on a non-diluted basis, creating substantial ownership concentration and potential dilution concerns.
- Regulatory Risk Remains Unchanged
- The filing states there were no material changes to the risk factors from the December 31, 2025 Form 10-K during the quarter ended June 30, 2026. Nevertheless, the company continues to face state regulatory changes involving THC/CBD limits, age verification, testing, labeling and packaging requirements.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 47.5%
- Operating margin
- -40.1%
- Segment
- Single reportable segment: hemp-derived CBD wellness products; Q2 2026 revenue $10.855 million versus $12.806 million in Q2 2025, down 15.2%.
What they said about what is next.
No numeric revenue or EPS guidance was provided in the 10-Q. Management expects continued SG&A cost containment in 2026 and believes cash, cash equivalents and short-term investments will fund operations and planned capital expenditures for the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Charlotte's Web reported Q1 2026 revenue of $11.16 million, a decline of 9.0% from $12.26 million in Q1 2025, with a gross margin of 46.6% down from 50.8%. The company posted a net loss of $13.12 million compared to a…
- 10-K · March 31, 2026
- Charlotte’s Web presents a strategy focused on vertically integrated, premium hemp-derived and botanical wellness products and expansion into adjacent categories (functional mushrooms, minor cannabinoids, low‑dose THC).…
- 10-Q · August 13, 2025
- Charlotte’s Web posted Q2 revenue of $12,806,000, up $517,000 (+4.2%) versus Q2 2024, with gross profit improving to $5,990,000 (46.8% gross margin) from $2,582,000 (21.0%). Operating loss narrowed to $(4,072,000) from…
- 10-K · March 19, 2025
- Charlotte’s Web positions itself as a U.S. market leader in hemp-derived CBD and botanical wellness products, operating a single reportable segment (hemp-derived CBD wellness products) as of December 31, 2024. Strategic…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CWBHF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever